Sector Gamma AS Sells 6,000 Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH)

Sector Gamma AS lessened its position in shares of Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 18.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 25,712 shares of the medical equipment provider's stock after selling 6,000 shares during the quarter. Lantheus accounts for 0.8% of Sector Gamma AS's portfolio, making the stock its 29th biggest holding. Sector Gamma AS's holdings in Lantheus were worth $2,300,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Wilmington Savings Fund Society FSB purchased a new stake in Lantheus in the third quarter worth about $25,000. Kestra Investment Management LLC bought a new position in shares of Lantheus during the 4th quarter valued at approximately $27,000. UMB Bank n.a. increased its holdings in Lantheus by 31.5% in the 4th quarter. UMB Bank n.a. now owns 559 shares of the medical equipment provider's stock worth $50,000 after acquiring an additional 134 shares in the last quarter. World Investment Advisors LLC bought a new stake in Lantheus during the 3rd quarter worth approximately $60,000. Finally, Parkside Financial Bank & Trust lifted its holdings in Lantheus by 49.4% during the fourth quarter. Parkside Financial Bank & Trust now owns 847 shares of the medical equipment provider's stock valued at $76,000 after purchasing an additional 280 shares in the last quarter. Institutional investors own 99.06% of the company's stock.

Insider Buying and Selling at Lantheus

In other news, CFO Robert J. Jr. Marshall sold 10,000 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $100.52, for a total transaction of $1,005,200.00. Following the transaction, the chief financial officer now directly owns 113,860 shares of the company's stock, valued at approximately $11,445,207.20. This trade represents a 8.07 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Mary Anne Heino sold 53,107 shares of the stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $94.35, for a total value of $5,010,645.45. Following the completion of the transaction, the director now directly owns 440,399 shares in the company, valued at approximately $41,551,645.65. This trade represents a 10.76 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 64,109 shares of company stock valued at $6,110,806 in the last quarter. 1.50% of the stock is owned by insiders.

Remove Ads

Lantheus Price Performance

Shares of LNTH traded up $0.33 during midday trading on Tuesday, hitting $99.77. The stock had a trading volume of 529,526 shares, compared to its average volume of 935,433. Lantheus Holdings, Inc. has a 1 year low of $57.92 and a 1 year high of $126.89. The stock's 50 day moving average is $92.91 and its 200 day moving average is $96.45. The firm has a market cap of $6.83 billion, a PE ratio of 16.60 and a beta of 0.38.

Lantheus (NASDAQ:LNTH - Get Free Report) last announced its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.57 by ($0.23). Lantheus had a return on equity of 44.29% and a net margin of 28.57%. The firm had revenue of $391.11 million during the quarter, compared to the consensus estimate of $376.61 million. As a group, equities research analysts expect that Lantheus Holdings, Inc. will post 6.01 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

LNTH has been the subject of several recent analyst reports. JMP Securities reaffirmed a "market outperform" rating and issued a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. The Goldman Sachs Group initiated coverage on shares of Lantheus in a report on Wednesday, December 18th. They issued a "buy" rating and a $143.00 target price for the company. B. Riley cut their target price on shares of Lantheus from $127.00 to $122.00 and set a "buy" rating for the company in a report on Friday. Finally, Truist Financial upped their price target on shares of Lantheus from $120.00 to $127.00 and gave the company a "buy" rating in a research note on Thursday, February 27th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. According to data from MarketBeat.com, Lantheus currently has a consensus rating of "Moderate Buy" and an average target price of $129.43.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.